Cargando…

The clinical and experimental treatment of Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and comprises of multiple subtypes. The most relevant disease subtypes, grouped upon current insight in disease mechanisms, are nonsystemic (oligo- and polyarticular) JIA and systemic JIA (sJIA). In this rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nijhuis, L, Swart, J F, Prakken, B J, van Loosdregt, J, Vastert, S J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical and Experimental Treatment of…
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571000/ https://www.ncbi.nlm.nih.gov/pubmed/37074076 http://dx.doi.org/10.1093/cei/uxad045

Ejemplares similares

Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis
por: Nijhuis, Lotte, et al.
Publicado: (2019)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
por: Kip, Michelle M A, et al.
Publicado: (2022)

Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis
por: Vastert, SJ, et al.
Publicado: (2008)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

PReS-FINAL-2181: Recombinant il-1ra restores the il-18-nk cell axis in steroid naive systemic juvenile idiopathic arthritis
por: De Jager, W, et al.
Publicado: (2013)

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis
por: Boom, V., et al.
Publicado: (2015)

Dutch patients, caregivers and healthcare professionals generate first nationwide research agenda for juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2021)

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients
por: Swart, Joost F, et al.
Publicado: (2019)

4.5 Defective phosphorylation of the interleukin 18 receptor beta-chain causes impaired NK cell function in systemic onset Juvenile Idiopathic Arthritis
por: de Jager, W, et al.
Publicado: (2008)

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

PReS-FINAL-2342: Anti-TNFALPHA therapy targeys PKB/C-AKT induced resistance of effector cells to suppression in juvenile arthritis
por: Wehrens, E, et al.
Publicado: (2013)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2020)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study
por: van Dijkhuizen, E. H. Pieter, et al.
Publicado: (2019)

Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
por: Kip, Michelle M. A., et al.
Publicado: (2022)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

PReS-FINAL-2107: In vitro investigation into mesenchymal stromal cells as a potential therapeutic in juvenile arthritis
por: Wienke, J, et al.
Publicado: (2013)

Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis
por: Grazziotin, Luiza R., et al.
Publicado: (2022)

Systemic Juvenile Idiopathic Arthritis in two children; case report on clinical course, challenges in diagnosis and the role of FDG‐PET/CT‐scan
por: Sahba, S., et al.
Publicado: (2022)

Monocytes and neutrophils in the inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
por: ter Haar, N, et al.
Publicado: (2015)

Patient’s experiences with the care for juvenile idiopathic arthritis across Europe
por: van Dijkhuizen, E. H. Pieter., et al.
Publicado: (2018)

Heat shock protein 60 reactive T cells in juvenile idiopathic arthritis: what is new?
por: Vercoulen, Yvonne, et al.
Publicado: (2009)

Review: Enhancers in Autoimmune Arthritis: Implications and Therapeutic Potential
por: Peeters, Janneke G. C., et al.
Publicado: (2017)

Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis
por: Aeberli, Daniel, et al.
Publicado: (2016)

Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis
por: Doeleman, Martijn J H, et al.
Publicado: (2019)

Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study
por: Grazziotin, Luiza R., et al.
Publicado: (2022)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
por: Constantin, Tamas, et al.
Publicado: (2018)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

Patterns of clinical joint inflammation in juvenile idiopathic arthritis
por: Heckert, Sascha L, et al.
Publicado: (2023)

Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
por: García-De-Vicuña, Carmen, et al.
Publicado: (2013)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review
por: Kip, Michelle M. A., et al.
Publicado: (2019)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lam8fgb94iqo0lcg6qu1ufkoj7